Patent information
IP India · live recordAbstract
The present disclosure relates generally to novel molecules compositions and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.
Applicants
1Inventors
9Claims
18Specification
Show full textCollapse
We claim: 1. A compound selected from the group consisting of: (i) a compound of Formula (I): FORMULA I wherein: X is C, N, or CRg; Ri is a C1-C3 alkyl or cyclopropyl, or R! forms a link to X or R2; R2 is H, SH or alkyl; R3 is H or halo; R8 is H, Ci-Cealkyl, Ci-Cealkoxy or halo; A is absent or a linker; B is absent or a linker; and R4 is a 5-membered aryl or heteroaryl, optionally substituted with 1 or 2 substituents; or R4 is a 6-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents, or II ' 'p R4is Y K , where p is 0-10; M is CH, NH, orS;YisNH, CH, O or S; L is a linker or Z; and Z is NH2, OH, SH, alkyl, -COOH, or CONH2, (ii) a compound of Formula (II):
wherein: XisO, S, orN; Ri is H, Ci-C6alkyl, -COCHY2, -COCH2Y, haloalkyl, CH2CN, amino, OCH3, COOCH3, SO2CH3, COCHjOH, or -[NHC(R7)]n-M; R2 and R3 are independently H or halo; R4 is a 5-membered aryl or heteroaryl, optionally substituted with 1 or 2 substituents; or R4 is a 6-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R4 is Y P Where p is 0-10; M is CH, NH, or S; Y is NH, CH, O or S; L is a linker or Z; and Z is NH2, OH, SH, alkyl, -COOH, or CONH2; or R4 is a a carbohydrate, (iii) a compound of Formula (III): FORMULA III wherein: (a) n is 1; X and Y are oxygen atom; W is carbon atom; Z is absent; R! is hydrogen atom, hydroxyl, methoxy, amino, -NH-(CH2)P-R, where p is 0, 1, 2, 3, 4 or 5; R is hydrogen atom, amine, guanidine, piperazine, morpholine, NHCOCH3, NHS02CH3, NHS02-C6H5 or -L!-B-R7; L! is -(CH2)q-, -(CH2)q-CH=CH-(CH2)q-, _(CH2)q-0-(CH2)q-, -(CH2)q- NH-(CH2)q-, where q is 0, 1, 2 or 3; A and B are independently a cyclyl, heterocyclyl, aryl or heteroaryl, where the cyclyl, heterocyclyl, aryl or heteroaryl can be optionally substituted with 1, 2 or 3 substituents;
R7 is hydrogen atom, hydroxyl, halo, nitro, carboxylic acid, methyl ester of carboxylic acid, OMe, nitrile, C(NH)-NH2, amino, -NHCOCH3, NHS02CH3NHS02-benzene, where the benzene can be optionally and independently substituted at ortho, meta or para position; R2 is -L1-A-R7; R3 is H; R4 and R5 independently are hydrogen, halogen, hydroxyl, or -0-(CH2)t-R8, where Rg is Q-Cealkyl, amino, di(Ci-C6alkyl)amino, aminocyclopropane, aminocyclopentane, piperazino, or morpholine, and t is 0-10; or (b) n is 1; X and W are carbon atom, or X is carbon atom and W is nitrogen atom; Y is -NH(CH2)q-R6 or (CH2)q-R6, where q = 0 to 10; R6 is -COOH, amine, guanidine, piperazine, morpholine; Z is hydrogen, methyl, NHR, COCH3, S02CH3, or -NH-(CH2)i-COOH, where 1 is 0-10; Ri and R3 independently hydrogen atom, hydroxyl, methoxy, amino, or -Li- A-R6 R is CH3, -(CH2)p-CH3, where p= 0 to 10; U is -(CH2)n-, -(CH2)t-CH=CH-(CH2)t-, _(CH2)t-0-(CH2)t-, -(CH2)t-NH- (CH2)t-, where t is 0, 1, 2, or 3; A is cyclyl, heterocycly, aryl or heteroaryl, where the cyclyl, heterocycly, aryl or heteroaryl can be optionally substituted with 1, 2 or 3 substituents; R6 is hydrogen atom, hydroxyl, halo, nitro, carboxylic acid, methyl ester of carboxylic acid, OMe, nitrile, C(NH)-NH2, amino, -NHCOCH3, NHS02CH3NHS02-benzene, where the benzene can be optionally and independently substituted at ortho, meta or para position; R2 is hydrogen atom; R4 and R5 are independently hydrogen, halogen, hydroxyl, or -0(CH2)X-R8, where R8 is CrC6alkyl, amino, di( N(CH3)2, N(C2H5)2, N(7-Pr)2j aminocyclopropane, aminocyclopentane, piperazino or morpholine, and x is 0-10, or (c) n is 2; X and W are carbon atom; Y is -NH(CH2)q-R6 or (CH2)q-R6, where q = 0 to 10; R6 is -COOH, amine, guanidine, piperazine, morpholine;
Z is hydrogen, methyl, NHR, COCH3, S02CH3, or -NH-(CH2)i-COOH, where 1 is 0-10; Ri and R3 independently hydrogen atom, hydroxyl, methoxy, amino, or -Li-A-R6 R is CH3, -(CH2)P-CH3, where p= 0 to 10; U is -(CH2)n-, -(CH2)t-CH=CH-(CH2)t-, _(CH2)t-0-(CH2)t-, -(CH2)t-NH-(CH2),-, where t is 0, 1, 2, or 3; A is cyclyl, heterocycly, aryl or heteroaryl, where the cyclyl, heterocycly, aryl or heteroaryl can be optionally substituted with 1, 2 or 3 substituents; R6 is hydrogen atom, hydroxyl, halo, nitro, carboxylic acid, methyl ester of carboxylic acid, OMe, nitrile, C(NH)-NH2, amino, -NHCOCH3, NHS02CH3 NHS02-benzene, where the benzene can be optionally and independently substituted at ortho, meta or para position; R2 is hydrogen atom; R4 and R5 are independently hydrogen, halogen, hydroxyl, or -0(CH2)x-R8 where R8 is Ci-C6alkyl, amino, di( N(CH3)2, N(C2H5)2, N(7-Pr)2, aminocyclopropane, aminocyclopentane, piperazino or morpholine, and x is 0-10, and (iv) a compound of Formula (IV): FORMULA IV wherein: B is absent or a linker; and Ri is a 5-membered aryl or heteroaryl, optionally substituted with 1 or 2 substituents; or R! is a 6-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents; or R! is a fused ring 9-10-membered aryl or heteroaryl, optionally substituted with 1, 2 or 3 substituents, /) a compound of Formula (V):
FORMULA V wherein: X and Z are independently C or N; Y is C, N or O; Ri is H or -LrA; R2 and R3 are independently O or S; R4 is hydrogen, oxygen, sulphur, hydroxyl, methoxy or -L2-B; R5, R6, R7 and R8 are independently, hydrogen, hydroxyl, fluoro, chloro, bromo, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxyl, amino substituted hexose, or guanidine; L! is absent, a bond or a linker; L2 is absent, a bond or a linker; A and B are independently a cyclyl, heterocyclyl, aryl or heteroaryl, where cyclyl, heterocyclyl, aryl and heteroaryl can be optionally substituted with 1, 2 or 3 substituents, (vi) a compound of Formula (VI): FORMULA VI wherein: X and Z are independently C or N; Y is CH2, NH or O; Ri can be H, OH or -Li-A; R3 is hydrogen, OH, oxygen, sulphur, hydroxyl, methoxy or -L2-B; R4 is O or S; R5, R6, R7 and Rg are independently hydrogen, hydroxyl, halo, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxyl, amino substituted hexose, or guanidine;
L! is absent, a bond or a linker; L2 is absent, a bond or a linker; and A and B are independently cyclyl, heterocyclyl, aryl or heteroaryl, where cyclyl, heterocyclyl, aryl and heteroaryl can be optionally substituted with 1, 2 or 3 substituents, and (vii) a compound of Formula (VII): wherein: X is CHR12, C=R13, NH, S or O; YisOorS; Ri can be H, alkylamino, -OH, -NH(CH2)2NH2or -LrA; R2 and R3 are independently hydrogen, hydroxyl of or -L2-B; R4 and R5 are independently H, halo, hydroxyl, or -(CH2)n-0-(CH2)n-D-R8, - (CH2)n-NH-(CH2)n-D-R8; R8 is H, hydroxyl, halo, trifluoromehtyl, alkyl, alkoxy, acyloxy, amino, dialkylamino, -C02H, nitro, nitrile or-NHS02CH3; Ri2 is H, amino, hydroxyl, or thiol; R13 is O, S or NH; Li is absent, a bond or a linker; L2 is absent, a bond or a linker; A, B and D are independently cyclyl, heterocyclyl, aryl or heteroaryl, where cyclyl, heterocyclyl, aryl and heteroaryl can be optionally substituted with 1, 2 or 3 substituents; and n is 0, 1, 2 or 3. The compound of claim 1, wherein the compound is selected from the group consisting of:
3. A pharmaceutical composition comprising a compound of claim 1 or 2 and a pharmaceutical^ acceptable carrier or excipient. 4. A composition for topical application comprising a compound of claim 1 or 2. 5. A composition for oral administration comprising a compound of claim 1 or 2. 6. A composition for administration by injection comprising a compound of claim 1 or 2. 7. A composition comprising a polymer matrix and a compound of claim 1 or 2. 8. A method for treating an infection, the method comprising administering a therapeutically effective amount of a compound of claim 1 or 2 to a subject in need thereof. 9. The method of claim 8, wherein said infection is caused by a resitant pathogen. 10. The method of claim 8, wherein said infection is caused by a methicillin resistant or vancomycin-resistant pathogen. 11. The method of claim 8, wherein said infection is caused by a quinolone resistant pathogen. 12. A method for wound treatment, the method comprising applying a compound of claim 1 or 2 to a wound. 13. A method for preventing or reducing infection caused by an implant, the method comprising applying a compound of claim 1 or 2 to the implant. 14. A method for preventing or reducing infection caused by an implant, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof. 15. A method for the treatment of pneumonia, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof. 16. A method for the treatment of urinary tract infection, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof.
17. A method for the treatment of impetigo, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof. 18. A method for the treatment of acne, the method comprising administering a compound of claim 1 or 2 to a subject in need thereof. 19. A method of inhibiting or reducing biofilm formation, the method comprising applying a compound of claim 1 or 2 to a surface or biofilm.